CN1135972C - Mixed antigen medicine for treating benign and malignant skin lesion - Google Patents
Mixed antigen medicine for treating benign and malignant skin lesion Download PDFInfo
- Publication number
- CN1135972C CN1135972C CNB001310453A CN00131045A CN1135972C CN 1135972 C CN1135972 C CN 1135972C CN B001310453 A CNB001310453 A CN B001310453A CN 00131045 A CN00131045 A CN 00131045A CN 1135972 C CN1135972 C CN 1135972C
- Authority
- CN
- China
- Prior art keywords
- medicine
- dinitrochlorobenzene
- skin
- dinitrofluorobenzene
- malignant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to mixing antigen medicine for treating benign and malignant skin lesion. The basic components of the medicine are formed by the preparation of 30 to 80 % of dinitrochlorobenzene and 70 to 20 % of dinitrofluorobenzene, in order to improve the medicine effect so that the function is more mild, and the adverse reaction of the medicine to a human body is reduced, 2 to 10% of borneol and ledebouriella root is added in the medicine; the medicine can use anhydrous alcohol as basic component solvent so that tincture is manufactured. The present invention provides new safe and effective broad-spectrum immunity medicine for people, which is mainly used for treating skin optimum canker, alopecia areata, various kinds of benign skin lesion such as various warts, cutaneous papilloma, etc. which are caused by skin viruses, and skin and mucosa malignant lesion such as basal cell carcinoma, squamous cell carcinoma, malignant melanoma, cheilocarinoma, eczematoid carcinoma of nipple, etc.
Description
[technical field] the present invention relates to a kind ofly treat that skin is good, the medicine of malignant change, especially a kind ofly treats that skin is good, the hybrid antigen medicine of malignant change.
[technical background] is well-known, and dinitrochlorobenzene is a kind of chemical reagent as tuerculoderma at first, and is not to be medicine.Just the inventor after 1975 (inventor's paper " verruca vulgaris bring out immunologic rejection therapy " is published in the 332nd page of the 44th page of " medical sci-tech data " the 7th phase in 1975, " Chinese Medical Journal " 1979 the 6th phase) is used for the treatment of verruca vulgaris with dinitrochlorobenzene as medicine, the medicinal field of just having opened up dinitrochlorobenzene.Then, the inventor has passed through continuous exploration and research for many years again, has further widened the medicinal scope of dinitrochlorobenzene, successfully dinitrochlorobenzene is used for the treatment of malignant tumor, and has obtained good effect.Wherein representative paper " the immunologic rejection therapy of body surface malignant tumor " was published on the 306th page of " Chinese journal of dermatology " 1987 the 20th the 5th phase of volume.In addition, application number is in the 96118012.9 patent of invention description, disclosed " a kind of pharmaceutical composition that is used for deep tumor by local treatment and in the application of pharmacy ", and dinitrochlorobenzene is used for the treatment of tumor as medicine also once report.But the inventor finds in treatment clinical course, uses good, the malignant change of dinitrochlorobenzene treatment skin merely, and having ratio is 20%～25% incompatibility crowd.Wherein some people scribbles the dinitrochlorobenzene position and " blister " reaction can occur because itself is too responsive on the skin, brings certain misery to the patient, and causes secondary infection easily.
[summary of the invention] the present invention has overcome the deficiency of above-mentioned prior art, and it is a kind of by dinitrochlorobenzene and dinitrofluorobenzene mixed preparing that its purpose is to provide, and is used for the treatment of that skin is good, the hybrid antigen medicine of malignant change.
The present invention is achieved by the following technical programs.
A kind ofly treat that skin is good, the hybrid antigen medicine of malignant change, this medicine contains the base stock of being made up of dinitrochlorobenzene and dinitrofluorobenzene, and wherein the weight proportion of the dinitrochlorobenzene of this medicine and dinitrofluorobenzene is:
Dinitrochlorobenzene is 30%～80%;
Dinitrofluorobenzene is 70%～20%.
In order further to improve this medicine effect, make its effect gentle more, reduce human body to the untoward reaction that medicine produces, increased suitable crowd's ratio, can in said medicine, add the Borneolum Syntheticum that accounts for medicine base stock gross weight 2%～10%; Perhaps/and in said medicine, add the Radix Saposhnikoviae that accounts for medicine base stock gross weight 2%～10%.
Above-mentioned hybrid antigen medicine can be mixed with an amount of solvent and make tincture or unguentum.The drug level of making tincture or unguentum is to contain dinitrochlorobenzene and dinitrofluorobenzene hybrid antigen medicine 100～500 micrograms in every milliliter of (gram) solvent.Solvent can be selected dehydrated alcohol or acetone for use.
Said medicine can be with the solvent of an amount of dehydrated alcohol as dinitrochlorobenzene and dinitrofluorobenzene, and it is the tincture that every milliliter of dehydrated alcohol contains dinitrochlorobenzene and dinitrofluorobenzene hybrid antigen medicine 100～500 micrograms that this medicine is made concentration.
The present invention is owing to the hybrid antigen medicine with dinitrochlorobenzene, dinitrofluorobenzene has replaced the single antigen-drug of dinitrochlorobenzene, and Borneolum Syntheticum and Radix Saposhnikoviae have been added, and substituted the acetone solvent of traditional use with dehydrated alcohol, make that drug effect of the present invention is better, the effect milder, reduced patient's human body to the untoward reaction that medicine produced, made suitable crowd's proportional be increased to 80%～90%.
The present invention mainly is applicable to treatment skin benign ulcer, alopecia areata, precancerous lesion (leukoplakia, Paget ' s disease) and skin benign lesions such as the various warts that caused by dermovirus, cutaneous papilloma for people provide a kind of safe and effective wide spectrum immunologic pattern new drug; And skin and mucosa malignant change such as rodent ulcer, cutaneous squamous cell carcinoma, malignant melanoma, lip cancer, eczematoid carcinoma of nipple, scrotum Paget ' s disease.
With specific embodiment the present invention is described below [specific embodiment].
Embodiment 1, dinitrochlorobenzene and dinitrofluorobenzene are respectively got 40mg, and Borneolum Syntheticum and Radix Saposhnikoviae are respectively got 8mg, use anhydrous alcohol solution, and it is the tincture that every milliliter of dehydrated alcohol contains dinitrochlorobenzene and dinitrofluorobenzene hybrid antigen medicine 200 micrograms that this medicine is made concentration; Or dissolve in and make ointment in the oil and all can.
Embodiment 2, dinitrochlorobenzene and dinitrofluorobenzene are respectively got 50mg, get Borneolum Syntheticum 5mg, use anhydrous alcohol solution, and it is the tincture that every milliliter of dehydrated alcohol contains dinitrochlorobenzene and dinitrofluorobenzene hybrid antigen medicine 100 micrograms that this medicine is made concentration; Or dissolve in and make ointment in the oil and all can.
Embodiment 3, dinitrochlorobenzene and dinitrofluorobenzene are respectively got 100mg, get Radix Saposhnikoviae 4mg, use anhydrous alcohol solution, and it is the tincture that every milliliter of dehydrated alcohol contains dinitrochlorobenzene and dinitrofluorobenzene hybrid antigen medicine 100 micrograms that this medicine is made concentration; Or dissolve in and make ointment in the oil and all can.
Claims (4)
1, a kind ofly treat that skin is good, the hybrid antigen medicine of malignant change, this medicine contains the base stock of being made up of dinitrochlorobenzene and dinitrofluorobenzene, and wherein the weight proportion of the dinitrochlorobenzene of this medicine and dinitrofluorobenzene is:
Dinitrochlorobenzene is 30%～80%;
Dinitrofluorobenzene is 70%～20%.
2, hybrid antigen medicine according to claim 1 is characterized in that containing in the said medicine Borneolum Syntheticum of said medicine base stock gross weight 2%～10%.
3, hybrid antigen medicine according to claim 1 and 2 is characterized in that containing in the said medicine Radix Saposhnikoviae that accounts for said medicine base stock gross weight 2%～10%.
4, hybrid antigen medicine according to claim 1, it is characterized in that the said medicine solvent of dehydrated alcohol as dinitrochlorobenzene and dinitrofluorobenzene, making concentration is the tincture that every milliliter of dehydrated alcohol contains dinitrochlorobenzene and dinitrofluorobenzene hybrid antigen medicine 100～500 micrograms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001310453A CN1135972C (en) | 2000-12-29 | 2000-12-29 | Mixed antigen medicine for treating benign and malignant skin lesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001310453A CN1135972C (en) | 2000-12-29 | 2000-12-29 | Mixed antigen medicine for treating benign and malignant skin lesion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1360888A CN1360888A (en) | 2002-07-31 |
| CN1135972C true CN1135972C (en) | 2004-01-28 |
Family
ID=4594460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001310453A Expired - Fee Related CN1135972C (en) | 2000-12-29 | 2000-12-29 | Mixed antigen medicine for treating benign and malignant skin lesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1135972C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610667A (en) * | 2013-11-07 | 2014-03-05 | 广东药学院 | Novel preparation dinitrochlorobenzene (DNCB)/anhydrous ethanol solution for treating tumors |
| JP7353012B2 (en) | 2019-08-22 | 2023-09-29 | フジアン ヨンジン テクノロジー カンパニー リミテッド | Fluorobenzene production process by direct fluorination |
-
2000
- 2000-12-29 CN CNB001310453A patent/CN1135972C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1360888A (en) | 2002-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003585A (en) | Complexes of phosphate derivatives. | |
| JP2001010960A (en) | Topcal zinc composition | |
| WO1993000873A1 (en) | Composition and method for transdermal delivery of diclofenac | |
| CN105125446A (en) | Eaglewood extract with allergy-relieving and anti-allergy effects, and preparation method and application thereof | |
| CN1135972C (en) | Mixed antigen medicine for treating benign and malignant skin lesion | |
| CA2766630C (en) | Anti-wart pharmaceutical composition and method for treating wart | |
| CN104547288B (en) | Have effects that removing free radical dispels red and swollen external medicine composition, preparation and preparation method thereof | |
| CN107198721A (en) | A kind of compound phellodendron bark gel and preparation method for treating childhood eczema | |
| CN103142962B (en) | Foot protection composition, foot mask and preparation method of foot protection composition | |
| CN102872158B (en) | External drug combination for curing eczema and preparation method thereof | |
| JP3962666B2 (en) | Topical skin preparation | |
| Hwang et al. | Development and optimization of a methotrexate topical formulation | |
| MA26726A1 (en) | PHARMACEUTICAL COMPOSITION OF RESORCINOL, AND PROCESS FOR ITS PREPARATION | |
| CA1218608A (en) | Undecylenic acid as a treatment for herpes labialis | |
| CN111298075B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1303997C (en) | Method for preparing artemisine and its liposoluble derivatives emulsion | |
| CN105412191A (en) | Arnica long-acting sustained release preparation for treating contusions and preparation method thereof | |
| KR960004897B1 (en) | Process for preparing acne remedial agent comprising ginseng extraction and centella asiatica extraction | |
| JPH107581A (en) | Arginase activity promoter | |
| EP0213130B1 (en) | Trichloroacetortoxy-3,4,5,6-tetrachlorobenzoic acid chemoterapeutically active against cutaneous and subcutaneous benigne neoformations, process for its preparation and compositions conmtaining the same | |
| CN112891270B (en) | Cosmetic composition and preparation method and application thereof | |
| CN1679794A (en) | Chinese medicine composition with tyrosinase activity inhibition and use thereof | |
| CN101999998A (en) | Compound ligustrazine ferulate whitening cream | |
| CN1192774C (en) | Integerrimine liposome gel preparation and preparing method | |
| Bailey | Percutaneous absorption of tricyclic antidepressants: amitriptyline, nortriptyline, imipramine, and desipramine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |